Esophagogastric junction contractile integral abnormalities in patients with proton pump inhibitor-refractory symptoms

J Dig Dis. 2021 Sep;22(9):529-535. doi: 10.1111/1751-2980.13038. Epub 2021 Sep 2.

Abstract

Objectives: Esophagogastric junction contractile integral (EGJ-CI) is a novel indicator to evaluate quantitatively the esophagogastric junction (EGJ) barrier function. We aimed to assess the role of EGJ-CI in patients with refractory gastroesophageal reflux disease (GERD) symptoms and the correlation between EGJ-CI and impedance-pH monitoring characteristics.

Methods: In total 82 patients with proton pump inhibitors (PPIs)-refractory gastroesophageal reflux symptoms (heartburn or regurgitation) were enrolled. These patients were further divided into two groups based on their EGJ-CI value (39 mmHg·cm). The mean nocturnal baseline impedance (MNBI) was measured to explore its association with EGJ-CI.

Results: The median EGJ-CI in patients with PPI-refractory symptoms was 30.8 mmHg·cm. EGJ-CI was inversely correlated with acid exposure time and reflux episodes; while it was positively correlated with MNBI, distal contractile integral, lower esophageal sphincter basal pressure and integrated relaxation pressure. Patients were further divided into the high (n = 27) and low (n = 55) EGJ-CI groups using a cut-off value of 39.0 mmHg·cm. Patients with a low EGJ-CI had a lower MNBI level than those with a high EGJ-CI (2703 Ω vs 3545 Ω, P = 0.034).

Conclusions: In patients with PPIs-refractory symptoms, EGJ-CI is associated with acid exposure and conventional high-resolution manometry parameters. EGJ-CI may play an important role in the diagnosis and treatment of patients with refractory GERD.

Keywords: esophagogastric junction contractile integral; functional heartburn; high-resolution manometry; impedance-pH monitoring; refractory gastroesophageal reflux disease.

MeSH terms

  • Esophageal pH Monitoring
  • Esophagogastric Junction
  • Gastroesophageal Reflux* / drug therapy
  • Heartburn
  • Humans
  • Manometry
  • Proton Pump Inhibitors* / therapeutic use

Substances

  • Proton Pump Inhibitors